Alpha Tau Medical Ltd.
DRTS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DRTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DRTS
Alpha Tau Medical Ltd. is a clinical-stage oncology medical device company developing its Alpha DaRT technology for multiple cancer indications, with no revenue to date and a history of significant operating losses.
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 21 clinical trials · 1 catalyst for Alpha Tau Medical Ltd..
Alpha Tau Medical Ltd. is a clinical-stage oncology medical device company developing its Alpha DaRT technology for multiple cancer indications, with no revenue to date and a history of significant operating losses.
- Alpha Tau has not generated any revenue since inception and reported a net loss of $42.6M for the year ended December 31, 2025 [sec].
- As of December 31, 2025, the company had cash and equivalents of $12.2M and an accumulated deficit of $190,136 [sec].
- The Alpha DaRT technology is in clinical trials for skin, oral, pancreatic, prostate, lung, liver, and brain cancers [sec].
- The company's patent portfolio includes 140 issued patents and 240 pending patent applications worldwide as of December 31, 2025 [sec].
What works
- Alpha DaRT is a novel alpha-radiation platform designed to treat solid tumors, with potential applicability across a wide range of cancer types [sec].
- The company holds a substantial patent portfolio of 140 issued patents and 240 pending applications globally, providing intellectual property protection [sec].
- Alpha Tau is conducting clinical trials in multiple cancer indications, including pancreatic and brain cancers, which could expand its addressable market [sec].
What to weigh
- The company has no revenue and expects to continue incurring significant losses, with an accumulated deficit of $190,136 as of December 31, 2025 [sec].
- Cash and equivalents of $12.2M as of December 31, 2025 may require the company to seek additional funding to complete ongoing and planned clinical trials [sec].
- Alpha Tau faces substantial development and regulatory risks, including the need to obtain marketing authorization in the U.S. and certifications abroad before generating product revenue [sec].
- The company has not yet demonstrated the ability to successfully complete a pivotal trial or commercialize any product candidate [sec].
From the filings
Quoted directly from source documents.
No revenue generated to date and expectation of continued losses.
“We have not generated any revenue to date and may never be profitable.”
SEC filings · March 9, 2026
Cash and accumulated deficit as of December 31, 2025.
“As of December 31, 2025, we had an accumulated deficit of $190,136.”
SEC filings · March 9, 2026
Patent portfolio size as of December 31, 2025.
“As of December 31, 2025, our patent portfolio included 140 issued patents, 5 PCT applications pending and 240 pending patent applications”
SEC filings · March 9, 2026
Clinical trials in multiple cancer types.
“Our Alpha DaRT technology is currently in clinical trials for a number of forms of cancer, including skin, oral, pancreatic, prostate, lung, liver and brain cancers”
SEC filings · March 9, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · alpha dart — Phase 2 Readout: alpha dart — Topline results from the Phase 2 alpha dart trial are expected, which could provide key efficacy and safety data for the Alpha DaRT technology.
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Company has no revenue and expects significant losses to continue; accumulated deficit of $190,136 as of Dec 31, 2025 [sec].
- Need for additional funding — Cash of $12.2M may be insufficient to complete all planned trials; may need to raise capital on unfavorable terms [sec].
- Regulatory and clinical uncertainty — Alpha DaRT has not completed a pivotal trial; marketing authorization in the U.S. and abroad is uncertain and time-consuming [sec].
- Dependence on third parties — Clinical trials rely on third-party contractors and CROs, which could cause delays or increased costs [sec].
What to watch
- Topline data from the Phase 2 alpha dart trial expected by December 31, 2026 [catalyst].
- Cash runway and any future capital raises, given $12.2M cash as of December 31, 2025 [sec].
- Progress in obtaining FDA Investigational Device Exemptions (IDEs) for new trials [sec].
- Updates on patent prosecution and any intellectual property challenges [sec].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Alpha Tau Medical Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alpha Tau Medical Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.1 months
D/E 0.37 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~123d
0 buys · 12 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$15.1M
| Holder | Shares | Value |
|---|---|---|
| aquamarine financial (cayman) ltd | 721,501 | $5.1M |
| ark investment management llc | 292,134 | $2.1M |
| citadel advisors llc | 140,395 | $993K |
| levin capital strategies, l.p. | 106,423 | $752K |
| jane street group, llc | 102,839 | $727K |
| susquehanna international group, llp | 83,438 | $590K |
| geode capital management, llc | 53,399 | $378K |
| wells fargo & company/mn | 49,300 | $349K |
| private advisor group, llc | 47,583 | $336K |
| millennium management llc | 46,445 | $328K |
Showing top 10 of 46 institutional holders of Alpha Tau Medical Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 3.4
- Shares short
- 1,018,069
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DRTS short interestFrequently asked questions
What is the AI investment thesis for Alpha Tau Medical Ltd.?
Alpha Tau Medical Ltd. is a clinical-stage oncology medical device company developing its Alpha DaRT technology for multiple cancer indications, with no revenue to date and a history of significant operating losses.
What is Alpha Tau Medical Ltd.'s next catalyst?
Alpha Tau Medical Ltd.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: alpha dart" — expected December 31, 2026.
Who is the CEO of Alpha Tau Medical Ltd.?
Mr. Uzi Sofer is the chief executive officer of Alpha Tau Medical Ltd. (DRTS).
Where is Alpha Tau Medical Ltd. headquartered?
Alpha Tau Medical Ltd. (DRTS) is headquartered in Jerusalem, Israel.
What therapeutic areas does Alpha Tau Medical Ltd. focus on?
Alpha Tau Medical Ltd. develops therapies across Oncology, Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.